S270: LONGER-TERM ANALYSIS OF EFFICACY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA ENROLLED IN THE BELIEVE STUDYMaria Domenica Cappellini, Vip Viprakasit, Alì Taher et al.|HemaSphere|2022Cited by 6
Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on DialysisKarthik Ramasamy, Pieter Sonneveld, Pamela Bacon et al.|Blood|2015Cited by 6
Phase 2 Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): An Updated Safety AnalysisKatja Weisel, Pieter Sonneveld, Meletios Α. Dimopoulos et al.|Clinical Lymphoma Myeloma & Leukemia|2017Cited by 2
P1466: EFFECT OF LUSPATERCEPT ON BONE MINERAL DENSITY IN PATIENTS WITH BETA‑THALASSEMIA ENROLLED IN THE PHASE 3 BELIEVE TRIALThomas D. Coates, Alì Taher, Maria Domenica Cappellini et al.|HemaSphere|2023Cited by 1
Safety Results of a Phase 2 Multicenter, Open-Label Study of Pomalidomide (CC-4047) Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal ImpairmentKatja Weisel, Pieter Sonneveld, Meletios Α. Dimopoulos et al.|Blood|2016Cited by 0